MammaPrint genomic profiling is changing how doctors treat breast cancer patients with hormone receptor-positive and HER2-negative tumors. Medical experts say that this test helps identify which patients can be spared from strong chemotherapy without affecting their chances of recovery. Dr. Lee Schwartzberg, a respected oncologist, explained that MammaPrint, along with the BluePrint test, allows health providers to make more accurate choices for their patients.
For those with low and ultra-low risk, genomic information shows they can safely use only hormone-blocking therapy, called endocrine therapy. This spares them from the harsh side effects of chemotherapy, making their treatment much easier. In contrast, patients who have a higher risk according to their test results may still need more aggressive treatment, including anthracycline-based chemotherapy.
Experts point out that these genomic tests do not work alone. Doctors still need to look at other important factors, including each patient’s medical details and their own wishes. Combining this information leads to truly personalized care, helping ensure patients get the treatment that fits their situation best.
Pharmacists also have a key part to play in this process. They work closely with the rest of the oncology team. Pharmacists often help choose proper genomic tests and teach patients about their treatment. They also support patients during therapy, especially by helping manage side effects common with chemotherapy.
As genomic profiling like MammaPrint becomes more common, the approach to breast cancer treatment is becoming more targeted. Better tools are helping healthcare teams avoid over-treatment but still keep patients safe and healthy. This careful matching of therapy to individual risks brings hope for more comfortable and effective care for many facing breast cancer.
